Balloon-Expandable Valve Outdoes Itself

The objective of this paper recently published in J Am Coll Cardiol Intv was to compare the outcomes of transcatheter aortic valve replacement (TAVR) with the new Sapien 3 Ultra vs. Sapien 3.

La válvula balón expandible se supera a sí misma

Successful implantation was extremely high with both balloon-expandable devices, which also had a very low adverse event rates. However, Sapien Ultra was significantly better than Sapien 3 in terms of paravalvular leak.

Both valves are made of bovine pericardium, with a cobalt-chromium stent plus a low-profile delivery system and high radial force. Sapien Ultra additionally has a polyethylene external skirt, which increases the device height by 40%, providing a 50% bigger contact surface with the native valve so as to improve annular sealing. The release system features differences too.

This registry included all consecutive patients who underwent TAVR with Sapien 3 and Sapien Ultra between 2014 and 2020. Propensity score matching was used to compare both arms.

A total of 310 matched patients were included (155 for each device). After propensity score matching, no difference was detected in baseline clinic characteristics.


Read also: Low-Carb Diet and Coronary Artery Calcium Progression.


Procedures were more frequently done under conscious sedation with Sapien Ultra (97.4% vs. 71.6%; p < 0.001) and pre-dilation was significantly less (42.6% vs. 85.2%; p < 0.001).

In-hospital results, including implantation success (91.6% vs. 95.5%; p = 0.165), major vascular complications (12.3% vs. 11.0%; p = 0.723), and pacemaker implantation (5.8% vs. 4.5%; = 0.608) were comparable between Sapien 3 and Ultra, respectively. 

The postprocedural gradient was similar (13.2 ± 5.7 mmHg vs. 13.1 ± 4.7 mmHg; = 0.829) and so were the rates for moderate and higher paravalvular leak (1.3% vs. 2.7%; p = 0.414).


Read also: AHA 2020 | Post-TAVR Anticoagulation in Patients with Atrial Fibrillation.


The significant difference in favor of Sapien Ultra was in mild leak with a rate that was less than half the rate for Sapien 3 (18.7% vs. 43%; p < 0.001).

Conclusion

With excellent results in both devices, adding a polyethylene skirt in the Sapien Ultra device managed to reduce the rate of mild paravalvular leak to less than half.

j-jcin-2020-07-013

Original Title: Transcatheter Aortic Valve Replacement With Balloon-Expandable Valves Comparison of SAPIEN 3 Ultra Versus SAPIEN 3.

Reference: Tobias Rheude et al. J Am Coll Cardiol Intv 2020;13:2631–8. https://doi.org/10.1016/j.jcin.2020.07.013.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...